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Abstract
Cathelicidins are mammalian proteins containing a C-terminal cationic antimicrobial domain.
Porcine PR-39 cathelicidin affects leukocyte biology. Mechanisms of action may involve alteration
of heparan sulfate proteoglycan-dependent functions in inflammatory cells. It was tested  whether
PR-39 affects human neutrophil migration and if such effects involve heparan sulphate
proteoglycans. Neutrophils were from forearm venous blood of healthy donors. Migration was
tested in modified Boyden chamber assays. Involvement of heparan sulfate proteoglycans was
tested by their chemical modification and by the use of specific antibodies. PR-39 induced migration
in neutrophils in a concentration dependent manner. Modification of heparan sulfate proteoglycans
with sodium chlorate inhibited migration whereas chemotaxis toward the chemoattractant formyl-
Met-Leu-Phe was not affected. Removal of heparan sulfates or chondroitin sulfates from the surface
of  neutrophils by heparinase or chondroitinase inhibited migration toward  PR-39. In conclusion,
antimicrobial PR-39 stimulates human neutrophil chemotaxis in a heparan sulfate proteoglycan-
dependent manner. Involvment of  syndecans is likely as both heparinase and chondroitinase were
abrogating. Data suggest active participation of heparan sulfate proteoglycans of neutrophils in
cathelicidin peptide-mediated regulation of the antimicrobial  host defense.
Findings
Peptides with in vitro antimicrobial activity have been
identified from several gene families. Two major antimi-
crobial peptide families in mammals are the defensins [1]
and the cathelicidin peptides [2-4]. It is known that the
defensin structure is based on a common beta sheet core,
which is stabilized by three disulfide bonds [1,2] but
cathelicidins are highly heterogeneous. Their conserved
cathelin domain sequence has been used as a genetic
probe enabling the discovery of numerous new members
of this family [4-10]. Circulating neutrophils, myeloid
bone marrow cells and epithelial surfaces are an impor-
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tant source of cathelicidine expression [7,11-14]. The
cathelicidin, prolin-arginine-rich 39 peptide (PR-39), first
isolated from the porcine small intestine [15] was also
identified in porcine neutrophils [16]. Different forms
occur and PR-39 isolated from porcine small intestine is
sligthly different in composition from that isolated from
porcine neutrophils [17]. PR-39 posseses antibacterial
activity [18] and has the ability to induce syndecan expres-
sion in wounds in animal studies [12]. PR-39 kills bacteria
by a mechanism that stops protein and DNA synthesis
after a lag period of about 8 min [18]. PR-39 is an inhibi-
tor of neutrophil function in injured mice, is involved in
metastatic activity of human tumor cells, and can induce
angiogenesis [1-3,19,20]. These observations suggest that
the efficacy of PR-39 is not species specific.
Heparan sulfate proteoglycans (HSPG) from endothelium
and leukocytes interact with P-selectin, an important
adhesion molecule regulating leukocyte adhesion and
migration [21]. HSPG localize to granules of myeloid cells
including monocytes and neutrophils [22], and expres-
sion of mRNA for syndecan core protein has been
detected in different types of leukocytes including neu-
trophils [23,24]. As PR-39 is abundantly expressed in
mammalian tissues and is best investigated among cathe-
licidins, our motivation in this project was to determine if
porcine PR-39 affects human neutrophil migration and
whether such effects involve HSPG.
Heparinase I and chondroitinase ABC were from Sigma
Chemical Corp. (St. Louis, MO, USA). PR-39 was synthe-
sized by solid-phase method with greater than 90% purity
[25]. Antibodies against the core-protein of syndecan-4
(D-16) and the ectodomain of this proteoglycan (5G9)
were affinity purified goat polyclonal antibodies raised
against peptides mapping with the respective regions of
the human syndecan-4 protein (both Santa Cruz Inc.,
Wiltshire, England). According to the manufacturers
instructions, suitability of its use has been demonstrated
for detection of syndecan-4 as well as for use as control
antibodies in siRNA studies. Other reagents not further
specified were also from Sigma. Neutrophils were
obtained from forearm venous blood of healthy volun-
teers, anticoagulated with 1.6 mg EDTA/mL of blood.
Neutrophil preparation was performed as described [26].
Cell preparations yielded > 95% neutrophils (by mor-
phology in Giemsa stains) and > 99% viability (by trypan
dye exclusion). Chemotaxis of neutrophils into cellulose
nitrate to gradients of soluble attractants was measured in
RPMI 1640/0.5% BSA using a 48-well microchemotaxis
chamber (Neuroprobe, Bethesda, MD, USA) in which a 5
μm pore-sized filter (Sartorius, Göttingen, Germany) sep-
arates the upper and lower chamber as previously
described [26]. When PR-39 was used as attractant, con-
centrations ranging from 10 mmol/L to 1 nmol/L were
tested. As positive control chemotactic agent in the lower
chamber fMLP was used. For some experiments cells were
pretreated with heparinase I, an enzyme that cleaves
highly sulfated regions of heparan sulfate-like gly-
cosaminoglycans at 2-O-sulfated uronic acids, for 50 min.
Thereafter cells were washed twice before testing for
chemotaxis. For other experiments cells were pretreated
with chondroitinase ABC also for 50 min that cleaves
chondroitin sulfate side chains of cell surface proteogly-
cans. Since it is known that sodium chlorate is able to
modify proteoglycan sulfation, we tested PR-39 chemo-
taxis after pre-treatment of cells for 20 min with sodium
chlorate. As neutrophil migration toward PR-39 might be
mediated via syndecan-4, chemotaxis experiments were
performed in the presence of monoclonal antibodies
toward the core-protein of syndecan-4 and a side chain of
this proteoglycan. Cells were incubated with these anti-
bodies for 20 min, washed twice and allowed to migrate
toward PR-39.
Data are expressed as mean and standard error of the
mean (S.E.M.). Means were compared by Kruskal-Wallis
analysis of variance and by Mann-Whitney u-test for non-
parametric samples (Abacus Concepts, Berkley, CA). A
difference with p < 0.05 was considered to be significant.
To determine whether PR-39 induces human neutrophil
chemotaxis, we tested in vitro migration of the cells at a
wide range of concentrations [10 mmol/L to 1 nmol/L].
PR-39 induced human neutrophil chemotaxis in a con-
centration dependent manner with a maximum effect at
10 μmol/L (data not shown). To investigate the role of
intact HSPG on the surface of neutrophils in PR-39-
induced cell migration, neutrophils were pretrated for 50
min with heparinase I or chondroitinase [both, 50 nU/mL
to 50 mU/mL] at 37°C, followed by two washing steps. As
glypicans carry heparan sulfate side chains but not chon-
droitin sulfate side chains, whereas syndecans carry both
[27], experiments were performed with both heparinase I
and chondroitinase. Results showed a concentration-
dependent reduction of migration by removal of these
two substrates from the cell surface, whereas chemotactic
effects of fMLP [10 nmol/L] were not affected (Fig. 1). To
investigate the effect of sodium chlorate which is known
to modify sulfation of proteoglycans and sulphated pro-
teins in cell culture, neutrophils were pretreated with
sodium chlorate [10 mmol/L to 40 mmol/L], washed, and
then allowed to migrate towards PR-39. Neutrophil chem-
otaxis to PR-39 was significantly inhibited by sodium
chlorate whereas chemotaxis toward the chemokine IL-8
used as alternative control attractant was not affected
(data not shown).
Because PR-39-induced chemotaxis was inhibited by
chondroitinase and heparinase I, we suggested theJournal of Inflammation 2006, 3:14 http://www.journal-inflammation.com/content/3/1/14
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involvement of syndecans but not glypicans by PR-39.
Moreover,  in vivo expression of syndecans has been
reported as being affected by PR-39 [12]. Therefore, chem-
otaxis of neutrophils toward PR-39 was tested in the pres-
ence of migration-blocking monoclonal antibodies to
syndecan-4 core protein or a syndecan-4 side chain
because this pathway was shown to affect the cell's motil-
ity. Neutrophils were again pre-treated with either of the
two antibodies or an isotype-matched IgG, and then
allowed to migrate toward PR-39 [10 μmol/L]. The anti-
bodies specifically inhibited neutrophil migration toward
PR-39 (Fig. 1).
In the present study, PR-39 stimulated human neutrophil
chemotaxis in a bell-shaped dose-response curve. PR-39 is
known to induce chemotaxis in porcine neutrophils [25].
As PR-39 is effective in improving survival in animals
models of severe sepsis [28,29]. the observation that PR-
39 affects neutrophil function accross different species
may be of relevance if PR-39 is further developed for
potential use in severe sepsis. In porcine leukocyte chem-
otaxis, peak responses occurred at 0.5 to 2 micromoles per
liter [25] which correlates well with PR-39 effects on
human neutrophils (data not shown). This finding sug-
gests that exogenous PR-39 may play a role not only in
animal but also in human inflammation.
For LL-37, the only human cathelicidin identified so far, it
was proposed that chemotactic responsiveness of leuko-
cytes involves formyl peptide receptor-like 1, and activa-
tion of this formyl peptide receptor-like 1 cross-
deactivates LL-37 responsiveness [30]. In mast cell
responses to cathelicidins, there may be two types of
receptors involved, a high affinity receptor responsible for
chemotaxis, and a low affinity receptor with undefined
function [31]. Detailed biochemical mechanisms or a bio-
chemical characterization of these binding sites, however,
remained unknown.
Antithrombin-III, a prototypical glycosaminoglycan lig-
and, has only recently been identified to exert direct
effects on cells of the innate immune system via HSPG
[26,32]. Already two decades ago, consensus sequences
for glycosaminoglycan recognition were determined as [-
X-B-B-X-B-X-] and [-X-B-B-B-X-X-B-X-] where B is the
probability of a basic residue and X is a hydropathic resi-
due, which form potential nucleation sites for the recog-
nition of polyanions in proteins [33]. As antimicrobial
peptides including defensins and cathelicidins contain
consensus sequences for HSPG recognition [34], we fur-
ther explored the roles of HSPG in mediating PR-39
effects in neutrophil migration. Heparan sulfate chains
abound on syndecans and glypicans which can bind a rep-
Effects of heparinase, chondroitinase and anti-syndecan 4 antibodies on PR-39-induced chemotaxis of neutrophils Figure 1
Effects of heparinase, chondroitinase and anti-syndecan 4 antibodies on PR-39-induced chemotaxis of neu-
trophils. Heparinase I (left panel) or chondroitinase (middle panel) was added to neutrophils. After an incubation (humidified, 
37°C/5% CO2) period of 50 min, cells were washed twice and chemotaxis assays were performed. PR-39 [10 μmol/L] was used 
as chemoattractant and fMLP [10 nmol/L] served as control attractant. Data are expressed as percent of medium control (pre-
treatment with medium), with a distance of migration toward fMLP of 79.8 ± 3.1 μm, towards PR-39 of 66.8 ± 1.3 (n = 4). Sta-
tistical analysis: Mann-Whitney U-test versus medium control, *, p < 0.05 after Kruskal-Wallis test, p < 0.05. Effects of 
antibodies to syndecan-4 core protein or syndecan-4 chain epitopes (right panel) were tested by preincubation of neutrophils 
for 20 minutes (humidified 37°C/5% CO2). After washing, cells were allowed to migrate toward PR-39 [10 μmol/L] in modified 
Boyden chambers using nitrocellulose micropore filters. Isotype matched IgG served as control. Results are given as mean ± 
SEM of the chemotaxis index, which is the ratio between the distance of migration toward attractant and that toward control. 
Distance of random migration was 40.0 ± 2.78 (n = 4). Statistical analysis: Mann-Whitney U-test versus no antibody, * p < 0.05 
after Kruskal-Wallis test p < 0.05.Journal of Inflammation 2006, 3:14 http://www.journal-inflammation.com/content/3/1/14
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ertoire of proteins. Thereby, HSPG can immobilize the lig-
ands, increase its local concentration, change its
conformation, present it to a signalling receptor and
enhance the formation of receptor-ligand signaling com-
plexes [35]. Modification of these heparan sulfate chains
could influence cell function. To further substantiate the
role of HSPG in the response of neutrophils to PR-39, cells
were pretreated with the sulfation inhibitor, sodium chlo-
rate [36]. This pretreatment dose-dependently inhibited
responiveness of the cells to PR-39. Moreover, of the two
families of membrane-bound HSPG, the syndecans, by
containing mixtures of the two major types of gly-
cosaminoglycan chains found in animal cells, namely
heparan sulfate and chondroitin sulfate, exemplify hybrid
proteoglycans. In contrast, the glypicans appear to contain
only heparan sulfate chains [37]. To examine if chondroi-
tin sulfate proteoglycans act as putative interaction site for
PR-39, neutrophils were treated with chondroitinase
before testing cell migration. Data imply that PR-39's
effects on cell migration are sensitive to both heparinase I
and chondroitinase suggesting that of HSPG, syndecans
mediate direct cellular actions of PR-39. By cleaving this
specific site enzymatically with heparinase or chondroiti-
nase or by chemically modifying them with sodium chlo-
rate, chemotactic effects of PR-39 were altered. These
observations not only confirm the role of HSPG in leuko-
cyte function but also functionally establish that synde-
cans are involved in signalling effects of the cathelicidin in
leukocytes.
The syndecan family of cell surface proteoglycans has
been implicated in a number of biological processes,
including blood coagulation, cell adhesion, signal trans-
duction and wound repair [38]. Originally found on epi-
thelial cells, syndecans were later shown to be present in
several other mesenchyma-derived cell types, including
fibroblast, smooth muscle cells, and neutrophils [28].
PR-39 has been shown to interact with a domain within
the integrin mediated signaling protein, namly p130(Cas)
[39], an assembling molecule of actin filaments which
promotes cell movement, cell migration, and cell spread-
ing in fibroblasts [40]. Identification of p130(Cas) as a
mediator of focal adhesion kinase-promoted cell migra-
tion [41] fits well to its interaction with PR-39, given the
finding that syndecan-4 modulates focal adhesion kinase
phosphorylation [42] and may be activated by PR-39 as
suggested by our observed inhibition of PR-39-induced
chemotaxis of neutrophils with antibodies to syndecan-4.
This hypothesis, however, requires biochemical confirma-
tion.
The data provided do not permit the conclusion that only
syndecan-4 mediates the chemotaxis of human neu-
trophils to PR-39. Other syndecans or glypicans may also
participate in coordinating the chemotactic response, as
additional cell surface proteoglycans harboring HS and/or
CS might also be involved.
To summarize, besides proposed involvement of formyl
peptide receptor-like 1, no signalling pathway for catheli-
cidins in neutrophils had been identified so far. Our
results provide strong evidence for interactions of PR-39
with proteoglycans on the surface of leukocytes. Biochem-
ical and functional tests identify syndecan-4 as a putative
acceptor site for PR-39 which contains consensus
sequences for glycosaminoglycan recognition. Our find-
ings may be of particular relevance if PR-39 proofs have a
therapeutic potential in neutrophil-mediated inflamma-
tory diseases.
Abbreviations
BSA – Bovine serum albumin
fMLP – formyl-Met-Leu-Phe
HSPG – Heparan sulfate proteoglycan
PR-39 – Prolin-arginine-rich 39 peptide
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
AD carried out the chemotaxis experiments and drafted
the manuscript. BM and NCK carried out the enzyme
digestion and antibody inhibition studies, respectively.
CRR, GR and JRP participated in the design of the study.
CJW conceived of the study, and participated in its design
and coordination and helped to draft the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
The study was partly supported by the „Verein zur Förderung von Forsc-
hung und Fortbildung in Klinischer Kardiologie und Intensivmedizin – Inns-
bruck, Österreich“.
References
1. Lehrer RI, Ganz T: Defensins of vertebrate animals.  Curr Opin
Immunol 2002, 14:96-102.
2. Lehrer RI, Ganz T: Cathelicidins: a family of endogenous anti-
microbial peptides.  Curr Opin Hematol 2002, 9:18-22.
3. Zaiou M, Gallo RL: Cathelicidins, essential gene-encoded mam-
malian antibiotics.  J Mol Med 2002, 80:549-61.
4. Zanetti M, Gennaro R, Romeo D: Cathelicidins: a novel protein
family with a common proregion and a variable C-terminal
antimicrobial domain.  FEBS Lett 1995, 374:1-5.
5. Zanetti M, Del Sal G, Storici P, Schneider C, Romeo D: The cDNA
of the neutrophil antibiotic Bac5 predicts a pro-sequence
homologous to a cysteine proteinase inhibitor that is com-
mon to other neutrophil antibiotics.  J Biol Chem 1993,
268:522-6.
6. Bagella L, Scocchi M, Zanetti M: cDNA sequences of three sheep
myeloid cathelicidins.  FEBS Lett 1995, 376:225-8.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Inflammation 2006, 3:14 http://www.journal-inflammation.com/content/3/1/14
Page 5 of 5
(page number not for citation purposes)
7. Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, Gen-
naro R: Identification of CRAMP, a cathelin-related antimi-
crobial peptide expressed in the embryonic and adult
mouse.  J Biol Chem 1977, 272:13088-93.
8. Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmunds-
son GH: FALL-39, a putative human peptide antibiotic, is
cysteine-free and expressed in bone marrow and testis.  Proc
Natl Acad Sci USA 1995, 92:195-9.
9. Storici P, Scocchi M, Tossi A, Gennaro R, Zanetti M: Chemical syn-
thesis and biological activity of a novel antibacterial peptide
deduced from a pig myeloid cDNA.  FEBS Lett 1994, 337:303-7.
10. Tossi A, Scocchi M, Zanetti M, Storici P, Gennaro R: PMAP-37, a
novel antibacterial peptide from pig myeloid cells. cDNA
cloning, chemical synthesis and activity.  Eur J Biochem 1995,
228:941-6.
11. Zanetti M, Litteri L, Gennaro R, Horstmann H, Romeo D:
Bactenecins, defense polypeptides of bovine neutrophils, are
generated from precursor molecules stored in the large
granules.  J Cell Biol 1990, 111:1363-71.
12. Gallo RL, Ono M, Povsic T, Page C, Eriksson E, Klagsbrun M, Bernfield
M: Syndecans, cell surface heparan sulfate proteoglycans, are
induced by a proline-rich antimicrobial peptide from
wounds.  Proc Natl Acad Sci USA 1994, 91:11035-9.
13. Frohm NM, Sandstedt B, Sorensen O, Weber G, Borregaard N,
Stahle-Backdahl M: The human cationic antimicrobial protein
(hCAP18), a peptide antibiotic, is widely expressed in human
squamous epithelia and colocalizes with interleukin-6.  Infect
Immun 1999, 67:2561-6.
14. Sorensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N: The
human antibacterial cathelicidin, hCAP-18, is synthesized in
myelocytes and metamyelocytes and localized to specific
granules in neutrophils.  Blood 1997, 90:2796-803.
15. Agerberth B, Lee JY, Bergman T, Carlquist M, Boman HG, Mutt V,
Jornvall H: Amino acid sequence of PR-39. Isolation from pig
intestine of a new member of the family of proline-arginine-
rich antibacterial peptides.  Eur J Biochem 1991, 202:849-54.
16. Shi J, Ross CR, Chengappa MM, Blecha F: Identification of a pro-
line-arginine-rich  antibacterial peptide from neutrophils
that is analogous to PR-39, an antibacterial peptide from the
small intestine.  J Leukoc Biol 1994, 56:807-11.
17. Shi J, Ross CR, Chengappa MM, Sylte MJ, McVey DS, Blecha F: Anti-
bacterial activity of a synthetic peptide (PR-26) derived from
PR-39, a proline-arginine-rich neutrophil antimicrobial pep-
tide.  Antimicrob Agents Chemother 1996, 40:115-21.
18. Boman HG, Agerberth B, Boman A: Mechanisms of action on
Escherichia coli of cecropin P1 and PR-39, two antibacterial
peptides from pig intestine.  Infect Immun 1993, 61:2978-84.
19. Ohtake T, Fujimoto Y, Ikuta K, Saito H, Ohhira M, Ono M, Kohgo Y:
Proline-rich antimicrobial peptide, PR-39 gene transduction
altered invasive activity and actin structure in human hepa-
tocellular carcinoma cells.  Br J Cancer 1999, 8:393-403.
20. Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W,
Rosenberg RD, Hampton TG, Sellke F, Carmeliet P, Simons M: PR39,
a peptide regulator of angiogenesis.  Nat Med 2000, 6:49-55.
21. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A: Differential
interactions of heparin and heparan sulfate glycosaminogly-
cans with the selectins. Implications for the use of unfrac-
tionated and low molecular weight heparins as therapeutic
agents.  J Clin Invest 1998, 101:877-89.
22. Parmley RT, Hurst RE, Takagi M, Spicer SS, Austin RL: Gly-
cosaminoglycans in human neutrophils and leukemic mye-
loblasts: ultrastructural, cytochemical, immunologic, and
biochemical characterization.  Blood 1983, 61:257-66.
23. Yeaman C, Rapraeger AC: Membrane-anchored proteoglycans
of mouse macrophages: P388D1 cells express a syndecan-4-
like heparan sulfate proteoglycan and a distinct chondroitin
sulfate form.  J Cell Physiol 1993, 157:413-25.
24. Yeaman C, Rapraeger AC: Post-transcriptional regulation of
syndecan-1 expression by cAMP in peritoneal macrophages.
J Cell Biol 1993, 122:941-50.
25. Huang HJ, Ross CR, Blecha F: Chemoattractant properties of
PR-39, a neutrophil antibacterial peptide.  J Leukoc Biol 1997,
61:624-9.
26. Dunzendorfer S, Kaneider N, Rabensteiner A, Meierhofer C, Reinisch
C, Romisch J, Wiedermann CJ: Cell-surface heparan sulfate pro-
teoglycan-mediated regulation of human neutrophil migra-
tion by the serpin antithrombin III.  Blood 2001, 97:1079-85.
27. Mertens G, Cassiman JJ, Van den Berghe H, Vermylen J, David G: Cell
surface heparan sulfate proteoglycans from human vascular
endothelial cells. Core protein characterization and anti-
thrombin III binding properties.  J Biol Chem 1992, 267:20435-43.
28. James PE, Madhani M, Ross C, Klei L, Barchowsky A, Swartz HM: Tis-
sue hypoxia during bacterial sepsis is attenuated by PR-39,
an antibacterial peptide.  Adv Exp Med Biol 2003, 530:645-52.
29. Madhani M, Barchowsky A, Klei L, Ross CR, Jackson SK, Swartz HM,
James PE: Antibacterial peptide PR-39 affects local nitric oxide
and preserves tissue oxygenation in the liver during septic
shock.  Biochim Biophys Acta 2002, 1588:232-40.
30. De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J,
Oppenheim JJ, Chertov O: LL-37, the neutrophil granule- and
epithelial cell-derived cathelicidin, utilizes formyl peptide
receptor-like 1 (FPRL1) as a receptor to chemoattract
human peripheral blood neutrophils, monocytes, and T cells.
J Exp Med 2000, 192:1069-74.
31. Niyonsaba F, Iwabuchi K, Someya A, Hirata M, Matsuda H, Ogawa H,
Nagaoka I: A cathelicidin family of human antibacterial pep-
tide LL-37 induces mast cell chemotaxis.  Immunology 2000,
106:20-6.
32. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ: Syndecan-
4 as antithrombin receptor of human neutrophils.  Biochem
Biophys Res Commun 2001, 287:42-6.
33. Cardin AD, Weintraub HJ: Molecular modeling of protein-gly-
cosaminoglycan interactions.  Arteriosclerosis 1989, 9:21-32.
34. Andersson E, Rydengard V, Sonesson A, Morgelin M, Bjorck L,
Schmidtchen A: Antimicrobial activities of heparin-binding
peptides.  Eur J Biochem 2004, 271:1219-26.
35. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J,
Zako M: Functions of cell surface heparan sulfate proteogly-
cans.  Annu Rev Biochem 1999, 68:729-77.
36. Wadstrom T, Ljungh A: Glycosaminoglycan-binding microbial
proteins in tissue adhesion and invasion: key events in micro-
bial pathogenicity.  J Med Microbiol 1999, 48:223-33.
37. Kjellen L, Lindahl U: Proteoglycans: structures and interac-
tions.  Annu Rev Biochem 1991, 60:443-75.
38. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose
EJ:  Biology of the syndecans: a family of transmembrane
heparan sulfate proteoglycans.  Annu Rev Cell Biol 1992, 8:365-93.
39. Chan YR, Gallo RL: PR-39, a syndecan-inducing antimicrobial
peptide, binds and affects p130(Cas).  J Biol Chem 1998,
273:28978-85.
40. Honda H, Nakamoto T, Sakai R, Hirai H: p130(Cas), an assem-
bling molecule of actin filaments, promotes cell movement,
cell migration, and cell spreading in fibroblasts.  Biochem Bio-
phys Res Commun 1999, 262:25-30.
41. Cary LA, Han DC, Polte TR, Hanks SK, Guan JL: Identification of
p130Cas as a mediator of focal adhesion kinase-promoted
cell migration.  J Cell Biol 1998, 140:211-21.
42. Wilcox-Adelman SA, Denhez F, Goetinck PF: Syndecan-4 modu-
lates focal adhesion kinase phosphorylation.  J Biol Chem 2002,
277:32970-7.